Inactive Instrument

Sunshine Biopharma, Inc. Stock Other OTC

Equities

US8677811064

Pharmaceuticals

Sales 2024 * 44.4M Sales 2025 * 100M Capitalization 3.3M
Net income 2024 * 2M Net income 2025 * 16M EV / Sales 2024 * 0.07 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.03 x
P/E ratio 2024 *
1.11 x
P/E ratio 2025 *
0.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 71 09-10-14
Director of Finance/CFO 62 09-10-14
Chief Operating Officer - Jan. 24
Members of the board TitleAgeSince
Director/Board Member 70 22-01-31
Chief Executive Officer 71 09-10-14
Director of Finance/CFO 62 09-10-14
More insiders
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
More about the company